The Vanguard Group, Inc. Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed Form 8.3 under the Irish Takeover Panel Act of 1997. This disclosure pertains to their interest in Avadel Pharmaceuticals plc, detailing relevant securities representing more than 1% of Avadel's shares. As of January 21, 2026, Vanguard holds a position of 5,860,981 ordinary shares, representing 6.02% of Avadel's securities.

Additionally, Vanguard executed two transactions: a purchase of 1,330 shares at 21.51 USD per share, and a sale of 219 shares at the same price. No cash-settled or stock-settled derivative transactions are reported in their disclosure. Moreover, Vanguard has not entered any indemnity or option arrangements, nor any agreements concerning voting rights related to these securities.

This disclosure is part of compliance with Rule 8.3, requiring detailed reporting by those holding significant interest in a company under potential acquisition or merger.